Literature DB >> 8145794

Rifabutin prophylaxis and uveitis.

J D Fuller, L E Stanfield, D E Craven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8145794     DOI： 10.1056/NEJM199405053301816

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease.

Authors:  J I Kuper; M D'Aprile
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients.

Authors:  P Kelleher; M Helbert; J Sweeney; J Anderson; J Parkin; A Pinching
Journal:  Genitourin Med       Date:  1996-12

Review 4.  Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

Authors:  R Heylen; R Miller
Journal:  Genitourin Med       Date:  1996-08

Review 5.  Drug-induced uveitis. Incidence, prevention and treatment.

Authors:  F W Fraunfelder; J T Rosenbaum
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

6.  Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.

Authors:  C B Trapnell; C Jamis-Dow; R W Klecker; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 7.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

8.  Anterior uveitis associated with rifabutin medication in AIDS patients.

Authors:  K Becker; M Schimkat; H Jablonowski; D Häussinger
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 9.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.